AzTrials
AzTrials

Kidney Disease, ChronicDRC_LExSNCT06910475

Physical Exercise and Biomolecular Analysis to Reduce Uremic Toxins in Chronic Kidney Disease: An Exploratory Study

A study testing Resistance training, Endurance training and Concurrent training in people with Kidney Disease, Chronic and Kidney Failure Chronic, run by Catholic University of Brasília at 1 site in Brazil.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record
Search all trials

Trial summary

The accumulation of uremic toxins is detrimental to physiological systems and induces premature biological aging. Renal function assessment methods, such as predictive formulas, may be influenced by ancestry in Brazilians, given the country's ethnic diversity, resulting in inaccurate estimates. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Resistance training, Endurance training and Concurrent training
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,600 participants
Where
1 siteBrazil
Study dates
1 Apr 2025to 31 Dec 2035
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • those diagnosed with chronic kidney disease and presenting persistent albuminuria (>300mg/g) following KDIGO guidelines;
  • metabolic syndrome {i.e., type 2 diabetes mellitus, arterial hypertension (blood pressure >180/100mmHg), overweight or obesity, and dyslipidemia};
  • no complications arising from pre-existing clinical metabolic diseases (i.e., diabetic coma, ketoacidosis, hyperosmolarity, and/or uncontrolled diabetes), as evaluated by a nephrologist;
  • absence of neurodegenerative, musculoskeletal, lupus erythematosus, or congenital kidney disease;
  • no apparent cardiovascular complications, such as heart failure, severe arrhythmia, angina, or cerebrovascular disease;
  • no comorbidities that limit performance in physical tests or training;
Show all 9Show fewer
  • not engaged in exercise programs for at least six months prior to the start of the experimental protocol;
  • no smoking or alcohol consumption behavior;
  • D-dimer values within normal range (220-500 ng/mL FEU)

Who cannot join

  • regularly engage in physical exercise,
  • have suffered a stroke in the last 6 months and/or present autoimmune diseases,
  • have unstable cardiac dysfunctions, such as: uncontrolled coronary artery disease, aneurysm at risk of rupture, uncontrolled arrhythmia, uncontrolled hypertension (SBP > 190 mmHg and/or DBP > 100 mmHg), heart attack in the last 3 months;
  • infectious conditions, Hb < 8 in the last routine monthly hemodialysis exam;
  • musculoskeletal pain;
  • fever;
  • resting SpO2 lower than 94%;
  • restriction by the clinical team.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Brazil1 site

  • Catholic University of Brasília

    Taguatinga, Federal District, 71966-700

Other trials in Brazil

About this study

Official title: Exerkidney: A Tracking of Uremic Toxins, Exerkines, Genetic Aspects, Physical Fitness, Body Composition, and The Effects of Physical Training in People With Chronic Kidney Disease at Different Stages

The accumulation of uremic toxins is detrimental to physiological systems and induces premature biological aging. Renal function assessment methods, such as predictive formulas, may be influenced by ancestry in Brazilians, given the country's ethnic diversity, resulting in inaccurate estimates. On the other hand, physical exercise is an important ally in treating chronic kidney disease (CKD) as it induces metabolic changes that help slow the disease's progression. Additionally, the anti-aging effect conferred on those who engage in physical exercise is widely recognized. However, investigations into the impact of physical exercise on the concentration of uremic toxins and biological aging in patients with chronic kidney disease and their relationship with ancestry are still in the early stages and inconclusive. The investigators aim to track uremic toxins, exerkines, genetic aspects, nutritional profile, physical fitness, body composition, and the effects of different types of physical training (periodized and progressive) in people with chronic kidney disease at various stages. Additionally, to verify associations between these factors and their effects on different physiological systems. This is a triple-blind randomized clinical trial, with a 10-year follow-up of patients. The sampling will be non-probabilistic in terms of accessibility or convenience. Adult volunteers of both biological sexes aged 18 or older, with chronic kidney disease in conservative treatment (stages 2, 3, 4, and 5, n~400), patients undergoing renal replacement therapy (hemodialysis or peritoneal dialysis, n~800), and transplant recipients (n~400) will be recruited from different hemodialysis centers. After being grouped by disease stage, patients will be randomized according to pre-training variables and then allocated to the following groups: control group (CTL; at least n~100), strength training (ST; at least n~100), aerobic training (AT; at least n~100), and combined training (CT; at least n~100). The patients will undergo evaluations of body composition, cardiorespiratory capacity, muscle strength, autonomic nervous system function, and nutritional, psychological, and biomolecular assessments. The training protocols will be adjusted according to the patient's physical capacity, always considering periodization and progression.

Read the detailed description

This study is a randomized, triple-blind clinical trial with a 10-year follow-up. Sampling is non-probabilistic by accessibility or convenience. Recruitment: Recruitment will be widely promoted via mass media (social media, TV) to invite individuals with chronic kidney disease. Additionally, the investigators will receive referrals from partner physicians and public-private partnerships. Participants will be recruited from dialysis clinics, outpatient clinics, and hospitals in Brasília, DF, respecting privacy and confidentiality. The investigators aim to recruit a minimum of 1,600 adult patients (both sexes), aged 18+, divided into those with CKD in conservative treatment (stages 2, 3, 4, 5, n~400), renal replacement therapy (hemodialysis and peritoneal dialysis, n~800), and kidney transplant patients (n~400). Participants will receive all pertinent information about the study and potential risks and benefits. Those who agree will sign an informed consent form. Following consent, each patient will undergo a comprehensive history assessment, including exercise, medical, and nutritional histories, along with an analysis of their medical records. Monthly evaluations will cover all procedures and interventions outlined for their allocated group. Patient Randomization: Participants will be stratified by CKD stage (conservative treatment, hemodialysis, peritoneal dialysis, and post-transplant) and further randomized by pre-training variables (biological sex, body weight, BMI, and body composition), using an online application. Patients will then be allocated to one of four groups: control (CTL; n~100), strength training (ST; n~100), aerobic training (AT; n~100), and combined training (CT; n~100). Assessments: Body Composition: BMI, DEXA, 7-Skinfold (Jackson and Pollock protocol); Cardiopulmonary Capacity: Anaerobic threshold, Fitcheck, respiratory muscle strength, spirometry; Muscle Strength: 1RM, handgrip, isokinetic force and power, E-lastic portable dynamometer; Autonomic Nervous System: Cardiovascular regulation during deep breathing, Valsalva maneuver with handgrip exercise, post-exercise ischemia, cold-water hand immersion, perceived exertion, respiratory rate, heart rate, arterial oxygen saturation, HRV, BPV, spontaneous baroreflex sensitivity, EEG, cognitive assessment; Nutritional Assessment: 24-hour dietary recall, food frequency questionnaire; Psychological Assessment: Quality of life (KDQOL-SF36), sleep quality, Beck Depression Inventory; Biochemical and biomolecular Assessments: Biological sample collection (urine, feces, saliva, blood) for measurements of creatinine, cystatin-C, leptin, GDF-15, TGF-β, insulin, albumin, SIRT-1, C-reactive protein, irisin, intact FGF23, C-terminal FGF23, ADMA, soluble α-Klotho, glycated hemoglobin (HbA1c), total cholesterol, LDL-c, HDL-c, triglycerides, myeloperoxidase, lipoperoxidation assay, paraoxonase-1, total antioxidant capacity, nitric oxide, lactate, creatine kinase, uremic toxins (KIM-1, NGAL, indoxyl sulfate, p-cresyl sulfate, TMAO, TNF-α, IL-6, ADMA, exercise-related proteins, BDNF, DNA and RNA isolation (salting out method), telomere length and telomerase activity, microRNA expression analysis, HPLC quantification, and identification of compounds by MALDI TOF/TOF mass spectrometry); Ancestry Analysis: Ancestry genome-wide association stratification; Training Protocols: Physical training protocols will include strength, aerobic, and combined training; Statistical Analysis: Sample size is calculated for 99% power (1-β = 0.99) with an alpha of 5% (α = 0.05) and effect size of 0.1, resulting in 400 patients. Descriptive analysis will be presented in tables and charts. Normality and homogeneity of data will be tested by Shapiro-Wilk and Levene's tests. For normally distributed data, group comparisons will be conducted by two-way ANOVA with Tukey's post-hoc test for significant differences. Non-normally distributed data will be analyzed by Kruskal-Wallis with Dunn's post-test, with results expressed as medians and interquartile ranges. Significance will be set at p < 0.05, with effect size calculated by Cohen's d. Associations between variables will be evaluated by Spearman's correlation. To minimize type II error, the investigators will calculate variations before and after training as Δ = post-training - pre-training. Principal Component Analysis (PCA) and individual variability analysis will use delta results to identify key variables affecting estimated glomerular filtration rate. This analysis will use the Past software (v4.09). Typical error and smallest worthwhile change (SWC) will be calculated per Swinton et al. (2018). Effect size will follow Hopkins' scale: <0.2 (trivial), 0.2-0.6 (small), 0.6-1.2 (moderate), 1.2-2.0 (large), 2.0-4.0 (very large), >4.0 (extremely large). Additionally, K-means cluster analysis, an unsupervised machine learning method, will identify patterns based on numerical distance between variables. Statistical analyses will use Microsoft Excel® 2010, GraphPad Prism 6.0, R and RStudio (v4.1.3), and SPSS (v.21.0).

Being tested
Resistance training, Endurance training, Concurrent training
Keywords
Exerkines, uremic toxins, physical training, physical exercise, indoxyl sulfate, p-Cresyl sulfate, hippuric acid, trimethylamine N-oxide, asymmetric dimethylarginine, redox balance, inflammation, tumor necrosis factor alpha, interleukin, leptin, irisin, BNDF, ancestry, telomere
Medical subject headings
Renal Insufficiency, Chronic, Motor Activity, Inflammation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Resistance trainingOther

    The training program will follow a periodized approach, starting with a low total volume (loads x sets x repetitions), ensuring gradual adaptation, patient safety, and performance progression. Strength training will begin 48 hours after muscle strength tests.Sessions will occur 2 to 4 times per week on non-consecutive days. Each session will include 6-12 exercises, with 1-3 seconds for concentric and eccentric actions, 6-20 repetitions, 1-6 sets, and 1-3 minutes of rest. Intensity will be gauged by perceived exertion, ranging from "easy" to "hard," with load adjustments every 2 months based on progress.Patients undergoing hemodialysis may perform the sessions during or between treatments. Portable equipment like free weights, ankle weights, and resistance bands will be used.

  • Endurance trainingOther

    Training sessions will be conducted 2 to 4 times per week on non-consecutive days. Patients will perform aerobic training on different ergometers, namely: bicycle, treadmill, and stair climber. The choice will depend on the patient's needs/abilities and/or equipment availability. The load will be adjusted between 50% and 100% of the ventilatory threshold, according to the patient's cardiorespiratory capacity. The duration of the training will vary between 10 and 60 minutes, always starting with low load and volume, with gradual progression to ensure patient comfort and safety.

  • Concurrent trainingOther

    Training sessions will be conducted 2 to 6 times per week, alternating between strength training one day and aerobic training the next, as described above. As patients improve their physical fitness, strength and aerobic training may be performed on the same day.

Study groups in NCT06910475
Study groupRoleWhat they receive
Conservative CKDExperimentalPatients with CKD under conservative treatment.
Receives: Other: Resistance training; Other: Endurance training; Other: Concurrent training
HemodialysisExperimentalPatients with CKD under hemodialysis treatment.
Receives: Other: Resistance training; Other: Endurance training; Other: Concurrent training
Peritonial dialysisExperimentalPatients with CKD under peritonial dialysis.
Receives: Other: Resistance training; Other: Endurance training; Other: Concurrent training
Transplant patientExperimentalTransplant patient
Receives: Other: Resistance training; Other: Endurance training; Other: Concurrent training
Control group - conservativeNo interventionPatients with CKD under conservative treatment.
Control group - HemodialysisNo interventionPacients under hemodialysis treatment
Control group - peritonial dialysisNo interventionPatients under peritonial dialysis
Control group - Transplant patientNo interventionTransplant patient

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Concentrations of uremic toxins - Indoxyl sulfate

    Serum concentration of Indoxyl sulfate (µmol/L) will be measured.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  2. Concentrations of uremic toxins - p-Cresyl sulfate

    Serum concentration of p-Cresyl sulfate (µmol/L) will be measured.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  3. Concentrations of uremic toxins - hippuric acid

    Serum concentration of hippuric acid (µmol/L) will be measured.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  4. Concentrations of uremic toxins - trimethylamine N-oxide

    Serum concentration of trimethylamine N-oxide (µmol/L) will be measured.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  5. Concentrations of uremic toxins - screening

    Other uremic toxins may also be identified through miRNA expression, high-performance liquid chromatography (HPLC) and mass spectrometry (MALDI TOF/TOF) identified peptides, with spectra processed via FlexControl and FlexAnalysis.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  6. Serum albumin

    The serum albumin (mg/dL) will be measured in duplicate using the automated chemical analyzer (COBAS c111 system, Roche Diagnostics, Switzerland).

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  7. Creatinine

    Creatinine (mg/dL) will be measured in duplicate using the automated chemical analyzer (COBAS c111 system, Roche Diagnostics, Switzerland).

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  8. Cystatin C levels

    Cystatin C levels (mg/dL) will be measured in duplicate using the automated chemical analyzer (COBAS c111 system, Roche Diagnostics, Switzerland).

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  9. Estimation of renal function in patients undergoing conservative treatment

    The values of creatinine and cystatin C values will be applied to the formula proposed by Inker (2012) to estimate the glomerular filtration rate (eGFR).

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

Secondary outcomes (56)

  1. Anthropometric measures - weight

    Weight in kilograms.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  2. Cardiopulmonary capacity - Graded Incremental Test and Metalyzer 3B

    Graded Incremental Test: Conducted on a cycle ergometer with a stepped or ramped protocol, ECG is monitored for abnormalities by a cardiologist. Gas exchange (VE, VO₂, VCO₂ L/min) is measured using the Metalyzer 3B gas analyzer (Cortex Biophysik) calibrated with a 3L syringe, and mixed gas (4.9% CO₂, 17% O₂). Values are recorded during the last 20 seconds of each 3-minute stage. The anaerobic threshold is determined by VE/VO₂ (L/min) and VE/VCO₂ (L/min) ratios.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  3. Autonomic function - Cardiovascular Autonomic Regulation during Deep Breathing

    Patients should breathe deeply and slowly in sync with the rhythm of a metronome, completing one respiratory cycle every 10 seconds (i.e., respiratory rate = 6 cycles/min). The maneuver will be conducted for 1 minute and 20 seconds, corresponding to 8 respiratory cycles. After a 5-minute rest interval, the maneuver will be repeated. The highest heart rate during each inspiration will be subtracted from the lowest heart rate during the subsequent expiration. The average of the five largest responses will be used to interpret the heart rate response to deep breathing, which serves as a marker of cardiac vagal control.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  4. Nutritional profile - dietary recall

    Nutritional assessment will use a 24-hour dietary recall to determine each patient's average intake of food and nutrients. Detailed data on types and amounts (in grams) of foods consumed will be collected, allowing calculations of proteins, lipids, cholesterol, carbohydrates, fiber, vitamins, and minerals. Dietary Reference Intakes will be used to evaluate dietary adequacy, and data will be analyzed with the Webdiet Health Manager application.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  5. Telomere length

    Average telomere length will be measured in monocytes. Telomere length will be assessed using quantitative real-time PCR (qPCR) using specific primers. Electrophoresis and Quantification: Amplification products will be analyzed using agarose gel electrophoresis with ethidium bromide. Bands (~300 base pairs) will be quantified by densitometry using Image J® software, with standardized background enhancement and a fixed quadrant dimension.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  6. Exerkinas - serum levels of irisin

    Serum levels of irisin (ng/mL) will be measured pré and post-training using Human Enzyme-Linked Immunosorbent Assay (ELISA) Kit.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  7. Glycemic profile - fasting glucose

    Serum levels of fasting glucose (mg/dL) will be mesure using the automated chemical analyzer (COBAS c111 system, Roche Diagnostics, Switzerland).

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  8. Patient's quality of life

    Kidney Disease and Quality-of-Life Short Form (KDQOL-SF36): This questionnaire has 36 items across eight general health dimensions: physical functioning, limitations from physical health, emotional health, social functioning, mental health, pain, vitality, general health perception, and current health status vs. one year ago. The kidney-specific section includes eleven dimensions: symptoms/problems, effects on daily life, burden, work status, cognitive function, social interactions, sexual function, sleep, social support, dialysis staff encouragement, and patient satisfaction . The scoring procedure first transforms the raw precoded numeric values of items to the 0-100 possible range, with higher transformed scores always reflecting a better quality of life. Then, the items scale is averaged together to create the scale scores. The results of each scale vary from 0 to 100 (worst to best possible status).

    Measured: Every two months, over a follow-up period of at least 6 months and up to up to 10 years.

  9. Gut microbiota profile

    Patients will perform self-collection following the instructions provided in the OMNIgene•GUT kit (OMR-200). Instructions will be available through an educational video and a step-by-step guide. Samples will be homogenized and aliquots will be stored in Eppendorf tubes. Samples will be analyzed within three months of collection, following the manufacturer's instructions (DNA Genotek, Ottawa, Ontario, Canada).

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  10. Inflammatory profile - TNF-α, IL-6, IL-10, IL-11, IL-18 e FGF-23

    Inflammatory profile: tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) , interleukin-10 (IL-10), interleukin-11 (IL-11), interleukin-18 (IL-18), Fibroblast Growth Factor 23 (FGF-23) all in pg/mL will be measured using Human Enzyme-Linked Immunosorbent Assay (ELISA) Kit.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  11. Ancestry Assessment

    Genomic analysis will use DNA extracted from participants' blood samples. Genome-wide association studies (GWAS) will be applied to gather ancestry-related data, enhancing the precision of assessing ancestry's influence on renal function. Genome-Wide Association Ancestry Stratification: Ancestry analysis will be based on genetic and phenotypic data, performed by an external company to ensure result quality and reliability. GWAS techniques will identify genetic markers linked to various ancestral origins using blood-derived DNA. CD Genomics, a company specializing in genomic sequencing and genetic data analysis, will conduct the GWAS. The goal is to identify genetic variants associated with renal function across different stages of chronic kidney disease (CKD), incorporating participants' ancestry factors.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 ye Every two months, over a follow-up period of at least 6 months and up to 10 years.ars.

  12. Muscle strength - 1-repetition maximum

    Muscle strength will be evaluated through 1-repetition maximum (1-RM), expressed in kilograms-force (kgf)."

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  13. Anthropometric measures - height

    Height in meters

    Measured: Every two months, over a follow-up period of at least 6 months and up to up to 10 years.

  14. Anthropometric measures - Body mass index

    Weight (kg) and height (m) will be combined to report BMI in kg/m².

    Measured: Every two months, over a follow-up period of at least 6 months and up to up to 10 years.

  15. Body composition - DEXA

    Body composition will also be measured via Dual-energy X-ray Absorptiometry (DEXA) using a GE Lunar Prodigy® (GE Healthcare, Madison, WI, USA) with software version 4.7e. Measurements will be taken with patients fasting for 8+ hours.

    Measured: Every two months, over a follow-up period of at least 6 months and up to up to 10 years.

  16. Body composition - 7 Skinfold

    The Jackson and Pollock 7-Skinfold Protocol will also be used to estimate body density ( in millimeters) on skinfold measurements at seven body sites: biceps, triceps, subscapularis, suprailiac, middle axillary, abdomen, thigh, and leg. The value of measures will be applied to the equation proposed by Jackson and Pollock and converted to fat percentage based on the equation by Siri (1961).

    Measured: Every two months, over a follow-up period of at least 6 months and up to up to 10 years.

  17. Psychosocial aspects of patients

    Beck Depression Inventory: This tool has 21 groups of self-evaluative statements (0-3) regarding symptom severity. Scores of 0-9 = no depression, 10-15 = mild, 16-23 = moderate, and 24+ = severe depression.

    Measured: Every two months, over a follow-up period of at least 6 months and up to up to 10 years.

  18. Cardiopulmonary capacity - Fitcheck

    Fitcheck: The classic graded IT consists of 3-4 stages of 3 minutes each, with 1-minute pauses and 10-watt increases. Gas exchange (VE, VO₂, VCO₂ L/min) is assessed via Fitcheck® (Brazil, 2022), and this test is performed intra- and inter-dialysis for renal patients. The anaerobic threshold is determined by VE/VO₂ (L/min) and VE/VCO₂ (L/min) ratios.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  19. Cardiopulmonary capacity - Respiratory Muscle Strength

    Respiratory Muscle Strength: Pimax and Pemax are measured with a digital manovacuometer (MVD300-U Homed®) using nasal clips and oral adapters per ATS/ERS (2002). Spirometry: Conducted with Contec SP8B, measures (L/min) FVC, FEV1, FEV1/FVC, FEF25/75, FEF25/75/FVC seated, per ATS/ERS.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  20. Autonomic function - Valsalva Maneuver

    The Valsalva maneuver will be used to induce sudden and significant changes in blood pressure, enabling the assessment of heart rate, blood pressure, and muscle sympathetic nerve activity responses. The maneuver will be performed in the supine position. Patients will perform an expiratory effort for 15 seconds, maintaining an expiratory pressure of approximately 40 mmHg. The maneuver will be repeated two to three times, with at least a 10-minute interval between attempts, to enhance the reliability of the results.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  21. Autonomic function - Handgrip Exercise

    The maximum voluntary contraction will be determined as the highest force value obtained from three reproducible attempts. During these attempts, participants will be instructed to increase force abruptly and maintain a plateau for 2 to 3 seconds. The maximum force value will be used to calculate 30% of this value, which must be sustained for 2 minutes. During the exercise, the force trace will be projected onto the ceiling to help participants maintain the target force value as established in the protocol.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  22. Autonomic function - Post-Exercise Ischemia

    Circulatory occlusion will be performed by inflating a cuff positioned on the proximal portion of the arm. The occlusion will be applied before the end of the exercise to ensure that the metabolites produced during the exercise remain trapped in the arm, maintaining the activation of metaboreceptors even after exercise cessation.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  23. Autonomic function - Cold pressure test

    Cold exposure will be conducted by immersing one hand in a container filled with ice water. This maneuver activates pain receptors, which in turn provoke an increase in sympathetic activity. Therefore, this test will provide a means to assess the effect of increased sympathetic activity per se on the peripheral chemoreflex, independently of muscle metaboreflex activation.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  24. Autonomic function - handgrip strenght

    Handgrip strength ( kgf) will be measured using a digital force transducer specifically designed for this type of exercise (Grip Force Transducer, ADInstruments).

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  25. Autonomic function - respiratory rate

    Respiratory rate will be measured using a belt positioned on the lower portion of the thorax. This belt will monitor the expansion and contraction of the thoracic cavity during the respiratory cycle, allowing for precise measurement of respiratory rate (Piezo Respiratory Belt Transducer, ADInstruments). Respiratory rate, tidal volume, minute volume, end-tidal partial pressure of oxygen (PETO₂), and end-tidal partial pressure of carbon dioxide (PETCO₂) will be measured on a breath-by-breath basis using a metabolic analyzer (CPX Ultima, MedGraphics). The analyzer will be calibrated before each experiment following the manufacturer's instructions.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  26. Autonomic function - Heart rate

    Heart rate will be calculated from the electrocardiogram (ECG) signal, which will be measured using a single lead configuration (3 Lead Bio Amp Cable, ADInstruments). Also, heart rate will be measured using a three-lead electrocardiogram (Finometer, Finapres) for integration of simultaneous recordings to simultaneously record the various assessed variables on the same timescale, a system for converting analog signals to digital signals will be used (Powerlab, ADInstruments).

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  27. Autonomic function - Arterial Oxygen Saturation

    Arterial oxygen saturation will be measured using an oximeter positioned on the earlobe (Oximeter Pod/Ear Clip, ADInstruments).

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  28. Autonomic function - blood pressure

    Blood Pressure: Beat-to-beat blood pressure will be measured using the photoplethysmography method, with an appropriately sized cuff positioned on the middle finger of the non-dominant hand (Finometer, Finapres).

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  29. Autonomic function - Femoral Artery Measurements

    The diameter of the femoral artery and blood flow velocity will be assessed using Doppler ultrasound (Vivid 7, GE).

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  30. Autonomic function - Heart Rate Variability (HRV)

    HRV will be analyzed in time and frequency domains.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  31. Autonomic function - Spontaneous Baroreflex Sensitivity (SBS)

    The analysis of spontaneous baroreflex sensitivity will be performed using two methods: cross-spectral analysis and sequence analysis. Cross-spectral analysis will consist of calculating the square root of the ratio between the LF band power of HRV and the LF band power of SAP. Sequence analysis will involve identifying sequences of three or more consecutive beats where an increase/decrease in SAP is followed by an increase/decrease in the RR interval. This variable is largely determined by the vagal branch of the autonomic nervous system.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  32. Autonomic function - Instantaneous Cerebral Electrical Activity

    Instantaneous cerebral electrical activity will be assessed using the NeuroVirtual - Humanizing Diagnostics BWIII EEG Plus with 36 channels, following the 10-20 system and frequency adjustments through the equipment's application. The procedures will be conducted in accordance with the manufacturer's instructions.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  33. Nutritional profile - Food Frequency Questionnaire

    Food intake will also be assessed with the Food Frequency Questionnaire for hemodialysis patients (FFQ-HD), covering eleven food groups, including grains, vegetables, legumes, fruits, meats, dairy, oils, seasonings, beverages, sweets, and canned foods. Frequency and quantity over the past 12 months will be estimated, aided by a photo album for portion reference.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  34. Exerkinas - adiponectin

    Serum levels of adiponectin (µg/mL) will be measured pre and post-training using Human Enzyme-Linked Immunosorbent Assay (ELISA) Kit.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  35. Exerkinas - α-Klotho and sirtuin-1 (SIRT-1)

    Serum levels of α-Klotho (pg/mL) and sirtunin - SIRT-1 (pg/mL) will be measured pre and post-training using Human Enzyme-Linked Immunosorbent Assay (ELISA) Kit.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  36. Exerkinas - Sestrin

    Serum levels of sestrin (ng/mL) will be measured pré and post-training using Human Enzyme-Linked Immunosorbent Assay (ELISA) Kit.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  37. Exerkines - screening

    Additional exercise-related biomarkers will be screened through HPLC and identified by MALDI TOF/TOF MS (Bruker). Peptides and their purity will be assessed, and spectra will be analyzed using FlexControl 3.4 and FlexAnalysis 3.4.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  38. Glicemic profile - glycated hemoglobin

    Serum levels of glycated hemoglobin (mmol/mol) will be mesure using the automated chemical analyzer (COBAS c111 system, Roche Diagnostics, Switzerland).

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  39. Glycemic profile - insulin

    Serum levels of insulin (pmol/L) will be mesure using the automated chemical analyzer (COBAS c111 system, Roche Diagnostics, Switzerland).

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  40. Glycemic profile - HOMA-IR

    The HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) is used to estimate insulin resistance based on fasting glucose and insulin levels. The values of fasting glucose and fasting insulin are applied in the following formula: Fasting Insulin(μU/mL)×Fasting Glucose(mg/dL)/405.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  41. Glycemic profile - HOMA-B

    The HOMA-B (Homeostatic Model Assessment for Beta-Cell Function) is used to estimate pancreatic beta-cell function based on fasting glucose and insulin levels. It helps assess how well the pancreas is producing insulin in response to blood glucose levels.The formula for HOMA-B is: Fasting Insulin(μU/mL)×360 /Fasting Insulin(μU/mL)×360.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  42. Lipid profile

    Total cholesterol (mg/dL), cHDL(mg/dL), cLDL (mg/dL), and triglycerides (mg/dL) will be measured using the automated chemical analyzer (COBAS c111 system, Roche Diagnostics, Switzerland).

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  43. Inflammatory profile - CRP

    Serum levels of C-reactive protein (CRP; mg/L) will be mesured using Human Enzyme-Linked Immunosorbent Assay (ELISA) Kit.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  44. Inflammatory profile - MPO, Leptin, GDF-15

    Serum levels of myeloperoxidase (MPO), leptin, Growth/differentiation factor 15 (GDF-15) all in ng/mL will be mesured using Human Enzyme-Linked Immunosorbent Assay (ELISA) Kit.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  45. Inflammatory profile - ADMA

    Serum levels of Asymmetric Dimethylarginine (ADMA; µmol/L) will be mesured using Human Enzyme-Linked Immunosorbent Assay (ELISA) Kit.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  46. Redox profile - TBARS e NOx

    Serum levels of Thiobarbituric acid reactive substances (TBARS) and nitric oxide (NOx) all in µmol/L will be mesured using Human Enzyme-Linked Immunosorbent Assay (ELISA) Kit.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  47. Redox balance - paraoxonase-1 and catalase

    Serum levels of paraoxonase-1 and catalase (all in U/mL) will be mesured using Human Enzyme-Linked Immunosorbent Assay (ELISA) Kit.

    Measured: Every two months, over a follow-up period of at least 6 months and up to Every two months, over a follow-up period of at least 6 months and up to 10 years.10 years.

  48. Redox profile - TROLOX

    Serum levels of total antioxidant capacity (µmol Trolox Eq/L) wil be mesured using Human Enzyme-Linked Immunosorbent Assay (ELISA) Kit.

    Measured: : Every two months, over a follow-up period of at least 6 months and up to 10 years.

  49. Redox balance - SOD

    Serum levels of superoxide dismutase (SOD; U/mg protein) will be mesured using Human Enzyme-Linked Immunosorbent Assay (ELISA) Kit.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  50. Telomerase Activity Measurement

    Telomerase activity will be measured in monocytes. Telomerase activity will be evaluated via the Telomeric Repeat Amplification Protocol (TRAP). RT-PCR for TRF1, TRF2, and POT1: To identify TRF1, TRF2, and POT1 genes, a Reverse Transcriptase reaction followed by PCR will be conducted using specific primers. Electrophoresis and Quantification: Amplification products will be analyzed using agarose gel electrophoresis with ethidium bromide. Bands (~300 base pairs) will be quantified by densitometry using Image J® software, with standardized background enhancement and a fixed quadrant dimension.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  51. Muscle strength - handgrip

    Muscle strength will be evaluated through handgrip dynamometry, expressed in kilograms-force (kgf).

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  52. Muscle strength - isokinetic dynamometry

    Muscle strength will be evaluated through isokinetic dynamometry, expressed in kilograms-force (kgf).

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  53. Muscle strength - e-lastic

    Muscle strength will be evaluated through e-lastic, portable dynamometry, expressed in kilograms-force (kgf).

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  54. Autonomic function - Stroke Volume

    Stroke volume will be estimated using the Modelflow method.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  55. Autonomic function - Cardiac Output

    Cardiac Output and Peripheral Vascular Resistance: These will be calculated based on the estimated stroke volume.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

  56. Autonomic function - Blood Pressure Variability (BPV)

    BPV will be analyzed in time and frequency domains.

    Measured: Every two months, over a follow-up period of at least 6 months and up to 10 years.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Apr 2025
  2. Study start1 Apr 2025
  3. Primary completion15 Mar 2026
  4. Study completion31 Dec 2035 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Factorial
Model description
The intervention of the study will consist of physical exercise, including aerobic exercise, resistance training, and concurrent training (a combination of both). These interventions will follow a structured and supervised training protocol to assess their effects on the selected outcomes.
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
1,600 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06910475
Sponsor's protocol ID
79266224.1.0000.002979266224.1
Other IDs
445068/2023-0
Acronym
DRC_LExS
Status last verified
Mar 2026
First submitted
3 Oct 2024
Last updated
18 Mar 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Resistance training, Endurance training and Concurrent training in people with Kidney Disease, Chronic and Kidney Failure Chronic, run by Catholic University of Brasília at 1 site in Brazil.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: enrolling by invitation, as of the sponsor's last update on 18 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Concentrations of uremic toxins - Indoxyl sulfate (time frame: Every two months, over a follow-up period of at least 6 months and up to 10 years.). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06910475.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Mar 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in